{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:09:37Z","timestamp":1790215777048,"version":"4.1.0"},"reference-count":161,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Statutory Subsidy Funds of the Department of Molecular and Cellular Biology","award":["SUB.D260.22.016"],"award-info":[{"award-number":["SUB.D260.22.016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>LAG-3 (Lymphocyte activation gene 3) protein is a checkpoint receptor that interacts with LSEC-tin, Galectin-3 and FGL1. This interaction leads to reduced production of IL-2 and IFN-\u03b3. LAG-3 is widely expressed in different tumor types and modulates the tumor microenvironment through immunosuppressive effects. Differential expression in various tumor types influences patient prognosis, which is often associated with coexpression with immune checkpoint inhibitors, such as TIM-3, PD-1 and CTLA-4. Here, we discuss expression profiles in different tumor types. To date, many clinical trials have been conducted using LAG-3 inhibitors, which can be divided into anti-LAG-3 monoclonal antibodies, anti-LAG-3 bispecifics and soluble LAG-3-Ig fusion proteins. LAG-3 inhibitors supress T-cell proliferation and activation by disallowing for the interaction between LAG-3 to MHC-II. The process enhances anti-tumor immune response. In this paper, we will review the current state of knowledge on the structure, function and expression of LAG-3 in various types of cancer, as well as its correlation with overall prognosis, involvement in cell-based therapies and experimental medicine. We will consider the role of compounds targeting LAG-3 in clinical trials both as monotherapy and in combination, which will provide data relating to the efficacy and safety of proposed drug candidates.<\/jats:p>","DOI":"10.3390\/ijms23179958","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T21:27:17Z","timestamp":1662067637000},"page":"9958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors"],"prefix":"10.3390","volume":"23","author":[{"given":"Natalia","family":"Sauer","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5477-5771","authenticated-orcid":false,"given":"Wojciech","family":"Szlasa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jonderko","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-0104","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"O\u015bliz\u0142o","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Kunachowicz","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-5440","authenticated-orcid":false,"given":"Julita","family":"Kulbacka","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-9720","authenticated-orcid":false,"given":"Katarzyna","family":"Kar\u0142owicz-Bodalska","sequence":"additional","affiliation":[{"name":"Department of Drugs Form Technology, Faculty of Pharmacy, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lecocq, Q., Keyaerts, M., Devoogdt, N., and Breckpot, K. (2021). The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time\u2019s a Charm. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010075"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: From molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s002510050411","article-title":"Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II","volume":"48","author":"Bruniquel","year":"1998","journal-title":"Immunogenetics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbamcr.2015.08.008","article-title":"Galectin 3 as a guardian of the tumor microenvironment","volume":"1863","author":"Ruvolo","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.3389\/fimmu.2020.615317","article-title":"LAG3\u2019s Enigmatic Mechanism of Action","volume":"11","author":"Graydon","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/eji.200939874","article-title":"Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4","volume":"40","author":"Woo","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.3389\/fimmu.2021.785091","article-title":"Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer","volume":"12","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.4049\/jimmunol.1401025","article-title":"Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling","volume":"193","author":"Bae","year":"2014","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Triebel","year":"2005","journal-title":"Immunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23244","DOI":"10.1002\/jcla.23244","article-title":"Ectopic expression of LAG-3 in non\u2013small-cell lung cancer cells and its clinical significance","volume":"34","author":"Ma","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.5114\/pjp.2021.114177","article-title":"Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer","volume":"72","author":"Xu","year":"2022","journal-title":"Pol. J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1096\/fasebj.10.7.8635694","article-title":"Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production","volume":"10","author":"Annunziato","year":"1996","journal-title":"FASEB J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"(2022, July 10). LAG-3 Modulation of Natural Killer Cell Immunoregulatory Function|The Journal of Immunology. Available online: https:\/\/www.jimmunol.org\/content\/202\/1_Supplement\/76.7.","DOI":"10.4049\/jimmunol.202.Supp.76.7"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ni.2936","article-title":"The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells","volume":"15","author":"Viant","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Marhelava, K., Pilch, Z., Bajor, M., Graczyk-Jarzynka, A., and Zagozdzon, R. (2019). Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111756"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a Cancer Immunotherapy Target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A","article-title":"Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)","volume":"32","author":"Workman","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.4049\/jimmunol.168.8.3874","article-title":"Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)","volume":"168","author":"Andreae","year":"2002","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/eji.1830241246","article-title":"Lymphocyte-activation gene 3\/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes","volume":"24","author":"Huard","year":"1994","journal-title":"Eur. J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0959-8049(01)00184-8","article-title":"T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): Role of LAG-3\/MHC class II interactions in cell-cell contacts","volume":"37","author":"Demeure","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ciraolo, E., Althoff, S., Ru\u00df, J., Rosnev, S., Butze, M., P\u00fchl, M., Frentsch, M., Bullinger, L., and Na, I.K. (2022). Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063207"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100079","DOI":"10.1016\/j.iotech.2022.100079","article-title":"Clinical landscape of LAG-3-targeted therapy","volume":"14","author":"Chocarro","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/nn.4597","article-title":"Transcriptomic analysis of purified human cortical microglia reveals age-associated changes","volume":"20","author":"Galatro","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nn.4216","article-title":"Adult mouse cortical cell taxonomy revealed by single cell transcriptomics","volume":"19","author":"Tasic","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"183776","DOI":"10.1126\/science.aah3374","article-title":"Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","article-title":"An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex","volume":"34","author":"Zhang","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11060-021-03721-x","article-title":"LAG-3 expression in the inflammatory microenvironment of glioma","volume":"152","author":"Mair","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"134386","DOI":"10.1172\/jci.insight.134386","article-title":"Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration","volume":"5","author":"Ott","year":"2020","journal-title":"JCI Insight"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1002\/ctm2.365","article-title":"LAG3 and its emerging role in cancer immunotherapy","volume":"11","author":"Wang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1002\/ijc.31661","article-title":"Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma","volume":"143","author":"Mathios","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1239005","DOI":"10.1080\/2162402X.2016.1239005","article-title":"LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma","volume":"5","author":"Deng","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Botticelli, A., Zizzari, I.G., Scagnoli, S., Pomati, G., Strigari, L., Cirillo, A., Cerbelli, B., Di Filippo, A., Napoletano, C., and Scirocchi, F. (2021). The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. J. Pers. Med., 11.","DOI":"10.3390\/jpm11070651"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/bjc.2013.645","article-title":"Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients","volume":"109","author":"Jie","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4+CD25highFoxp3+ regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fendo.2022.859013","article-title":"Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41419-020-03294-z","article-title":"A new risk factor indicator for papillary thyroid cancer based on immune infiltration","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_52","first-page":"3557","article-title":"Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like","volume":"104","author":"Giannini","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e18579","DOI":"10.1200\/JCO.2020.38.15_suppl.e18579","article-title":"Differential immune pathways in classic and mixed variants of anaplastic thyroid cancer","volume":"38","author":"Young","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdx368","article-title":"Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study","volume":"28","author":"Mehnert","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.21037\/atm-21-4481","article-title":"Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer","volume":"9","author":"Sun","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_56","first-page":"2190","article-title":"Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients","volume":"5","author":"Wei","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.yexcr.2017.09.026","article-title":"Function and regulation of LAG3 on CD4+CD25- T cells in non-small cell lung cancer","volume":"360","author":"Ma","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jtho.2017.01.019","article-title":"LAG-3 Protein Expression in Non\u2013Small Cell Lung Cancer and Its Relationship with PD-1\/PD-L1 and Tumor-Infiltrating Lymphocytes","volume":"12","author":"He","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Song, L., Wang, X., Cheng, W., Wu, Y., Liu, M., Liu, R., Zhang, S., Xia, H., Liu, H., and Tai, X. (2021). Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01796-w"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.18632\/oncotarget.23716","article-title":"Novel mutational landscapes and expression signatures of lung squamous cell carcinoma","volume":"9","author":"Xiong","year":"2018","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.18632\/oncotarget.26748","article-title":"An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma","volume":"10","author":"Givechian","year":"2019","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41379-021-00974-9","article-title":"Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: Correlations with clinicopathologic features and prognostic significance","volume":"35","author":"Shepherd","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1954761","DOI":"10.1080\/2162402X.2021.1954761","article-title":"Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry","volume":"10","author":"Park","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3233\/CBM-181278","article-title":"Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-\u03b3 in peripheral blood","volume":"23","author":"Li","year":"2018","journal-title":"Cancer Biomark."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41416-020-0810-1","article-title":"OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody","volume":"122","author":"Ohmura","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.33358","article-title":"Lymphocyte-activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein-Barr virus-positive and MLH1-defective gastric cancer patients","volume":"148","author":"Lv","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-014-0082-9","article-title":"The effect of immune microenvironment on the progression and prognosis of colorectal cancer","volume":"31","author":"Chen","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Rhyner Agocs, G., Assarzadegan, N., Kirsch, R., Dawson, H., Galv\u00e1n, J.A., Lugli, A., Zlobec, I., and Berger, M.D. (2021). Lag-3 expression predicts outcome in stage ii colon cancer. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080749"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e1448332","DOI":"10.1080\/2162402X.2018.1448332","article-title":"Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer","volume":"7","author":"Zhou","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/1440-1681.12992","article-title":"Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients","volume":"45","author":"Ma","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12967-020-02469-8","article-title":"Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis","volume":"18","author":"Guo","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1136\/jitc-2021-SITC2021.089","article-title":"89\u2005The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma","volume":"9","author":"Cheung","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1158\/1078-0432.CCR-17-0950","article-title":"Characterization of the immune microenvironment in hepatocellular carcinoma","volume":"23","author":"Yarchoan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CJI.0000000000000111","article-title":"Expansion of tumor-reactive T cells from patients with pancreatic cancer","volume":"39","author":"Meng","year":"2016","journal-title":"J. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Seifert, L., Plesca, I., M\u00fcller, L., Sommer, U., Heiduk, M., von Renesse, J., Digomann, D., Gl\u00fcck, J., Klimova, A., and Weitz, J. (2021). LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Cancers, 13.","DOI":"10.3390\/cancers13061297"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CJI.0000000000000283","article-title":"LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target","volume":"42","author":"Lee","year":"2019","journal-title":"J. Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1155\/2019\/8901649","article-title":"Data Mining of Prognostic Microenvironment-Related Genes in Clear Cell Renal Cell Carcinoma: A Study with TCGA Database","volume":"2019","author":"Chen","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","article-title":"Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer","volume":"21","author":"Giraldo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_82","first-page":"552","article-title":"LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma","volume":"8","author":"Ralser","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_83","first-page":"431","article-title":"Analysis of T-cell immune response in renal cell carcinoma: Polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity","volume":"72","author":"Angevin","year":"1997","journal-title":"J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/cas.13996","article-title":"Immune infiltration in renal cell carcinoma","volume":"110","author":"Zhang","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","article-title":"PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma","volume":"7","author":"Zelba","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e1305535","DOI":"10.1080\/2162402X.2017.1305535","article-title":"Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling","volume":"6","author":"Siska","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1538-7445.AM2015-2502","article-title":"Abstract 2502: Immunization with minicircle and mini-intronic DNA vectors induce LAG-3 expressing CD8+ T cells and inferior anti-tumor responses","volume":"75","author":"Colluru","year":"2015","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1007\/s00018-020-03459-1","article-title":"Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer","volume":"77","author":"Jafari","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-21-0121","article-title":"A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes","volume":"27","author":"Calagua","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e000482","DOI":"10.1136\/esmoopen-2018-000482","article-title":"New emerging targets in cancer immunotherapy: The role of LAG3","volume":"4","author":"Puhr","year":"2019","journal-title":"ESMO Open"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Westergaard, M.C.W., Milne, K., Pedersen, M., Hasselager, T., Olsen, L.R., Anglesio, M.S., Borch, T.H., Kennedy, M., Briggs, G., and Ledoux, S. (2020). Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12123828"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","article-title":"LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-4175","article-title":"TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer","volume":"25","author":"Fucikova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e1535730","DOI":"10.1080\/2162402X.2018.1535730","article-title":"Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer","volume":"8","author":"Klynning","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0000000000000608","article-title":"LAG-3 and GAL-3 in endometrial carcinoma: Emerging candidates for immunotherapy","volume":"39","author":"Friedman","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e1756116","DOI":"10.1080\/2162402X.2020.1756116","article-title":"Genomic and immunologic correlates of LAG-3 expression in cancer","volume":"9","author":"Panda","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Sun, W., Qin, X., Yuan, G., Li, N., Liang, J., Li, C., Li, C., Li, M., Zhao, X., and Zhang, H. (2021). Aberrant Expression of Fgl-1 and Lag-3 in Adenomyosis. preprint.","DOI":"10.21203\/rs.3.rs-263822\/v1"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"Eggink","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/0008-5472.CAN-18-1342","article-title":"Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs","volume":"78","author":"Varn","year":"2018","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e15086","DOI":"10.1200\/JCO.2020.38.15_suppl.e15086","article-title":"Immunohistochemistry analyses of LAG-3 expression across different tumor types and co-expression with PD-1","volume":"38","author":"Chen","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ijc.32785","article-title":"Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival","volume":"147","author":"Tu","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/PGP.0000000000000782","article-title":"The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia","volume":"41","author":"Cocks","year":"2022","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/annonc\/mdx557","article-title":"LAG-3\u00fe tumor infiltrating lymphocytes in breast cancer: Clinical correlates and association with PD-1\/ PD-L1\u00fe tumors","volume":"28","author":"Burugu","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_104","first-page":"2420","article-title":"Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-016-0783-4","article-title":"An immune stratification reveals a subset of PD-1\/LAG-3 double-positive triple-negative breast cancers","volume":"18","author":"Bottai","year":"2016","journal-title":"Breast Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13058-020-01380-w","article-title":"Differential PD-1\/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer","volume":"23","author":"Sobottka","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"561793","DOI":"10.3389\/fimmu.2021.561793","article-title":"Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"106113","DOI":"10.1016\/j.intimp.2019.106113","article-title":"The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy","volume":"78","author":"Du","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_109","first-page":"62","article-title":"Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer","volume":"30","author":"Stovgaard","year":"2022","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/0008-5472.CAN-14-2956","article-title":"Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity","volume":"75","author":"Donia","year":"2015","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/jid.2014.29","article-title":"Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: Involvement of LAG-3","volume":"134","author":"Camisaschi","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-018-0217-9","article-title":"LAG-3 inhibits the activation of CD4 + T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII","volume":"19","author":"Maruhashi","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2006.12.012","article-title":"CCL2\/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers","volume":"252","author":"Huang","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Souri, Z., Wierenga, A.P.A., Kroes, W.G.M., van der Velden, P.A., Verdijk, R.M., Eikmans, M., Luyten, G.P.M., and Jager, M.J. (2021). LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13174445"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","article-title":"Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade","volume":"21","author":"Taube","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_116","first-page":"e6352","article-title":"PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors","volume":"11","author":"Wang","year":"2019","journal-title":"Cureus"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"eabf5107","DOI":"10.1126\/scitranslmed.abf5107","article-title":"LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade","volume":"13","author":"Shen","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e1926762","DOI":"10.1080\/2162402X.2021.1926762","article-title":"Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients","volume":"10","author":"Machiraju","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2020.11.009","article-title":"Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma","volume":"21","author":"Adam","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood.V126.23.2661.2661","article-title":"The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 andtim-3 Expression","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1 + T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_125","unstructured":"(2022, July 10). Lymphocyte Activation Gene-3, a MHC Class II Ligand Expressed on Activated T Cells, Stimulates TNF-Alpha and IL-12 Production by Monocytes and Dendritic Cells\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/10072520\/."},{"key":"ref_126","first-page":"1555","article-title":"Bispecific Antibodies: From Research to Clinical Application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"Chen","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"S1361","DOI":"10.1016\/j.annonc.2021.08.2049","article-title":"53P Expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy","volume":"32","author":"Nurgalieva","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD41 T cells in PD-1 blockade against MHC-II\u2013expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2217\/fon-2018-0807","article-title":"AIPAC: A Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer","volume":"15","author":"Dirix","year":"2019","journal-title":"Future Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-139868","article-title":"A Phase 1, Open-Label Study of MGD013, a Bispecific DART\u00ae Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Sordo-Bahamonde, C., Lorenzo-Herrero, S., Gonz\u00e1lez-Rodr\u00edguez, A.P., Payer, \u00c1.R., Gonz\u00e1lez-Garc\u00eda, E., L\u00f3pez-Soto, A., and Gonzalez, S. (2021). LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13092112"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1535-7163.MCT-18-1376","article-title":"Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice","volume":"18","author":"Burova","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2019.37.15_suppl.2508","article-title":"First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), \u00b1 cemiplimab in patients (pts) with advanced malignancies","volume":"37","author":"Papadopoulos","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.1200\/JCO.2021.39.15_suppl.9515","article-title":"Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma","volume":"39","author":"Hamid","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2967\/jnumed.119.237180","article-title":"Light-Induced Radiosynthesis of 89 Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor","volume":"61","author":"Klingler","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1538-7445.AM2018-5626","article-title":"Abstract 5626: Preclinical characterization of Sym022, a novel anti-LAG3 antibody","volume":"78","author":"Grandal","year":"2018","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"v488","DOI":"10.1093\/annonc\/mdz253.023","article-title":"A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","volume":"30","author":"Spreafico","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"MAbs"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cpt.2091","article-title":"Depletion of LAG-3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781","volume":"109","author":"Ellis","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/ecco-jcc\/jjaa054","article-title":"Lymphocyte Activation Gene (LAG)-3 Is Associated with Mucosal Inflammation and Disease Activity in Ulcerative Colitis","volume":"14","author":"Slevin","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1158\/1538-7445.AM2018-3819","article-title":"Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies","volume":"78","author":"Savitsky","year":"2018","journal-title":"Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-18-0836","article-title":"TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo","volume":"18","author":"Ghosh","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41419-020-03173-7","article-title":"Quantifying the efficacy of checkpoint inhibitors on CD8+ cytotoxic T cells for immunotherapeutic applications via single-cell interaction","volume":"11","author":"Sullivan","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2018.36.15_suppl.3012","article-title":"Phase I\/II study of LAG525 \u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies","volume":"36","author":"Hong","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2019.37.15_suppl.2553","article-title":"Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies","volume":"37","author":"Uboha","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_150","first-page":"3776","article-title":"Original research: Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","volume":"10","author":"Tan","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_151","first-page":"A235","article-title":"387\u2005A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies","volume":"8","author":"Lin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jim.2018.02.003","article-title":"Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction","volume":"456","author":"Bhagwat","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"TPS4594","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4594","article-title":"A phase 1b\/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC)","volume":"39","author":"Plimack","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1158\/1538-7445.AM2017-4714","article-title":"Abstract 4714: Blockade of LAG-3 amplifies immune activation signatures and augments curative antitumor responses to anti-PD-1 therapy in immune competent mouse models of cancer","volume":"77","author":"Haines","year":"2017","journal-title":"Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2021.39.15_suppl.3584","article-title":"A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"39","author":"Garralda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11912-021-01040-y","article-title":"Improving Breast Cancer Responses to Immunotherapy\u2014A Search for the Achilles Heel of the Tumor Microenvironment","volume":"23","author":"Jenkins","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-19-3548","article-title":"FS118, a bispecific antibody targeting lag-3 and PD-L1, enhances T-cell activation resulting in potent antitumor activity","volume":"26","author":"Kraman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_158","first-page":"A240","article-title":"395\u2005A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy","volume":"8","author":"Yap","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e1943180","DOI":"10.1080\/2162402X.2021.1943180","article-title":"PD-L1\/LAG-3 bispecific antibody enhances tumor-specific immunity","volume":"10","author":"Jiang","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.4049\/jimmunol.179.6.4202","article-title":"A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells","volume":"179","author":"Brignone","year":"2007","journal-title":"J. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/9958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:21:46Z","timestamp":1760142106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/9958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":161,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms23179958"],"URL":"https:\/\/doi.org\/10.3390\/ijms23179958","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}